Tuesday, January 31, 2023
  • Landing Page
  • Shop
  • Contact
  • Buy JNews
Thetesttech
Advertisement
  • Home
  • Business
  • Tech
  • Games
  • Gadgets
  • News
  • Contact
No Result
View All Result
Thetesttech
  • Home
  • Business
  • Tech
  • Games
  • Gadgets
  • News
  • Contact
No Result
View All Result
Thetesttech
No Result
View All Result
Home News

Jan Van Deursen Success Story

thetestteh by thetestteh
December 16, 2022
in News
0
Jan Van Deursen Success Story
585
SHARES
3.2k
VIEWS
Share on FacebookShare on Twitter

The Remarkable Achievements of Jan Van Deursen

Dr. Jan Van Deursen has achieved considerable success. Using a mouse model in which the gene that regulates cell division, p16Ink4a, was removed, he was the first to demonstrate that It could accelerate aging. Identifying these cell cycle regulators emphasizes their importance in aging and cancer. And he was influential in developing the first targeted medicine for leukemia, which is currently used to treat patients.

For what purpose does Jan Van Deursen perform his daily work?

Dr. Jan Van Deursen is motivated by his passion for research and the opportunity to better people’s lives. He expects his research to improve cancer therapy and other fields where aging populations are becoming an increasing problem.

You might also like

Sourcegraph Series DecemberMillerTechCrunch: Get Up To Speed On All The Latest News!

Introducing Canadabased Usyoungcnbc: Canada’s Newest International TV Channel

The Twitter Team That’s POTUSing Trump’s Hashtag: Morsemashable

Here is some advice for ambitious people from Jan Van Deursen:

Dr. Jan Van Deursen states that if you want to be an entrepreneur or operate a business, you should never give up. Moreover, he encourages them to collaborate with optimistic individuals who share their objectives.

Dr. Jan Van Deursen has achieved considerable success.

Dutch-born Dr. Jan Van Deursen joined the human race in 1965. In 1992, he left school with a Ph.D. in molecular genetics from the University of Amsterdam. Dr. van Deursen studies the molecular pathways contributing to cell death and aging. His research team has investigated, in particular, how changes in protein abundance may start cell death and tissue senescence.

These investigations have resulted in the creation of anti-aging medications that suppress the activity of these proteins. In addition, Dr. Jan van Deursen was involved in developing Unity Biotechnology, a firm that manufactures anti-aging drugs. The initial medication for osteoarthritis, UBX0101, has commenced clinical testing. Van Deursen cycles and skis to unwind when he is not busy being a spouse and father of three children.

Jan Van Deursen, Ph.D., and His Fulfilling Career

Dr. Jan Van Deursen has worked for major pharmaceutical corporations such as Bayer, Johnson & Johnson, and Pfizer during his remarkable career.

The early work of Dr. Jan van Deursen centered on the discovery and development of alternative cancer treatments. His findings aided in the development of Taxol, a cancer medication authorized by the FDA in 1992.

Dr. Jan van Deursen founded Unity Biotechnology in 2011, a pharmaceutical research and development company specializing in anti-aging medicines. As an early pioneer in biomedical research, Van Deursen has contributed significantly to treating cancer and other diseases.

Dr. Jan Van Deursen has made a breakthrough contribution to cancer genetics. According to his research, a specific protein in cells guarantees the correct distribution of chromosomes during mitosis. This protein has been linked to cancer, accelerated aging, and senescence. The discoveries of Dr. Van Deursen will aid in developing new treatments for age-related disorders.

His research primarily relies on mice with varying gene expression levels (heterozygous and hypomorphic strains).

Several organs and tissues of aging species, including humans, accumulate senescent cells. Previously, This assumed that senescent, or “zombie,” cells were harmless; however, Jan van Deursen and his team discovered that removing senescent cells from mice significantly increases their longevity and avoids the onset of numerous age-related diseases. In 2011, Jan van Deursen co-founded Unity Biotechnology, intending to develop effective treatments for geriatric disorders like atherosclerosis, cardiac or kidney failure, osteoarthritis, Alzheimer’s disease, and macular degeneration.

In 2018, Unity Biotechnology went public on the NASDAQ under the “UBNT.” By developing novel medications, Jan van Deursen has retained his pioneering spirit and determination to remedy critical gaps in the treatment of the aged.

What inspired Jan Van Deursen to create Unity Biotechnology? The discovery that so-called “zombie cells” accelerate aging and age-related diseases in mice led Jan Van Deursen’s team to form Unity Biotechnology. The primary objective was to discover and develop medications with the required level of specificity to eradicate these cells in humans. There are now ongoing clinical trials with drugs that have the potential to cure age-related diseases, which is hopeful. It is beautiful that a dozen other businesses are engaged in similar endeavors. In preclinical models, the therapeutic use of the concept for age-related diseases has shown promise, and its application to humans could significantly enhance the health of the aged.

Previous Post

How to Install Peel and Stick Wall Murals

Next Post

Wants and Needs Lyrics

thetestteh

thetestteh

Related Posts

Sourcegraph Series DecemberMillerTechCrunch: Get Up To Speed On All The Latest News!
News

Sourcegraph Series DecemberMillerTechCrunch: Get Up To Speed On All The Latest News!

by thetestteh
January 20, 2023
Introducing Canadabased Usyoungcnbc: Canada’s Newest International TV Channel
News

Introducing Canadabased Usyoungcnbc: Canada’s Newest International TV Channel

by thetestteh
January 15, 2023
The Twitter Team That’s POTUSing Trump’s Hashtag: Morsemashable
News

The Twitter Team That’s POTUSing Trump’s Hashtag: Morsemashable

by thetestteh
January 12, 2023
Influential Women: Meet Susan Wojcicki, CEO Of Google And Trump Feind
News

Influential Women: Meet Susan Wojcicki, CEO Of Google And Trump Feind

by thetestteh
January 12, 2023
Sassa R350 grant and Sassa Status Check
News

Sassa R350 grant and Sassa Status Check

by thetestteh
December 19, 2022
Next Post
Wants and Needs Lyrics

Wants and Needs Lyrics

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recommended

Sourcegraph Series 2.6b: December Miller’s TechCrunch Review

Sourcegraph Series 2.6b: December Miller’s TechCrunch Review

January 12, 2023
Constructing

4 Essential Steps Included in Constructing a House

December 24, 2022

Categories

  • Animals
  • Business
  • Classifieds
  • Creativity
  • Education
  • Entertainment
  • Fashion
  • Flower
  • Food
  • Gadgets
  • Games
  • Global
  • Health
  • Home
  • Lifestyle
  • News
  • Personality
  • Software's
  • Sports
  • Tech
  • Transportation
  • Travel
  • Weather

Don't miss it

Student Loans
Education

Understanding Your Student Loans: A Guide for American Students

January 30, 2023
Mexico-Based AzevedoTech Raises $20M Series A, Reaffirming Latin America’s Growing Tech Scene.
Business

Mexico-Based AzevedoTech Raises $20M Series A, Reaffirming Latin America’s Growing Tech Scene.

January 30, 2023
Joe Biden’s Hawkfish MayschleiferVox Explained: How To Use It For Your Business
Business

Joe Biden’s Hawkfish MayschleiferVox Explained: How To Use It For Your Business

January 30, 2023
THC Gummies
Lifestyle

The Different Kinds of THC Gummies: Which One is Right for You?

January 30, 2023
Pipe 50M: AzevedoTech Crunch Reveals An Incubator Program To Help Startups Grow
Business

Pipe 50M: AzevedoTech Crunch Reveals An Incubator Program To Help Startups Grow

January 30, 2023
Exploring The Revolutionary Potential Of 50mann Azevedotech’s Pipe Technology
Business

Exploring The Revolutionary Potential Of 50mann Azevedotech’s Pipe Technology

January 30, 2023
Thetesttech

Welcome to the Test Tech guest post site! This blog is dedicated to providing readers with quality, practical information on testing and assessment.

© Copyright 2023, All Rights Reserved | The Test Tech | Owner of The Test Tech

No Result
View All Result
  • Home
  • Landing Page
  • Buy JNews
  • Support Forum
  • Pre-sale Question
  • Contact Us

© Copyright 2023, All Rights Reserved | The Test Tech | Owner of The Test Tech